The metalloprotease adamts8 displays antitumor properties through antagonizing egfr-mek-erk signaling and is silenced in carcinomas by cpg methylation

Molecular Cancer Research

Volumn 12, Issue 2, 2014, Pages 228-238

  Choi, Gigi C G ^a   Li, Jisheng ^a,b   Wang, Yajun ^a   Li, Lili ^a   Zhong, Lan ^a   Ma, Brigette ^a   Su, Xianwei ^a   Ying, Jianming ^a,c   Xiang, Tingxiu ^d   Rha, Sun Young ^e   Yu, Jun ^f   Sung, Joseph J Y ^f   Tsao, Sai Wah ^g   Chan, Anthony T C ^a   Tao, Qian ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SHANDONG UNIVERSITY   (China)

^c CANCER HOSPITAL   (China)

^d THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^e Yonsei University College of Medicine   (South Korea)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIFS 8; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; EPIDERMAL GROWTH FACTOR RECEPTOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CELL MIGRATION; CLONOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; METHYLATION; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STOMACH CARCINOMA;

ADAM PROTEINS; APOPTOSIS; CELL LINE, TUMOR; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 11; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS;

EID: 84896697034     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0195     Document Type: Article

References (39)

1. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8.
2. Liu YJ, Xu Y, Yu Q. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 2006;25:2452-67.
3. Moncada-Pazos A, Obaya AJ, Fraga MF, Viloria CG, Capellá G, Gausachs M, et al. The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer. J Cell Sci 2009;122(Pt 16):2906-13.
4. Viloria CG, Obaya AJ, Moncada-Pazos A, Llamazares M, Astudillo A, Capellá G, et al. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res 2009;69:4926-34.
5. Lo PH, Lung HL, Cheung AK, Apte SS, Chan KW, Kwong FM, et al. Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res 2010;70:5567-76.
6. Jin H, Wang X, Ying J, Wong AH, Li H, Lee KY, et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 2007;26:7490-8.
7. Tang BL. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001;33:33-44.
8. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008;90:369-79.
9. Porter S, Scott SD, Sassoon EM,Williams MR, Jones JL, Girling AC, et al. Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin Cancer Res 2004;10: 2429-40.
10. Llamazares M, Cal S, Quesada V, Lopez-Otin C. Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases- disintegrins with multiple thrombospondin-1 repeats and a unique GON domain. J Biol Chem 2003;278: 13382-9.
11. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007;42:113-85.
12. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999;274:23349-57.
13. Koo BH, Coe DM, Dixon LJ, Somerville RP, Nelson CM,WangLW, et al. ADAMTS9 is a cell-autonomously acting, anti-angiogenic metalloprotease expressed by microvascular endothelial cells. Am J Pathol 2010;176:1494-504.
14. Dunn JR, Reed JE, du Plessis DG, Shaw EJ, Reeves P, Gee AL, et al. Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. Br J Cancer 2006;94: 1186-93.
15. Dunn JR, Panutsopulos D, Shaw MW, Heighway J, Dormer R, Salmo EN, et al. METH-2 silencing and promoter hypermethylation inNSCLC. Br J Cancer 2004;91:1149-54.
16. Demircan K, Gunduz E, Gunduz M, Beder LB, Hirohata S, Nagatsuka H, et al. Increased mRNA expression of ADAMTS metalloproteinases in metastatic foci of head and neck cancer. Head Neck 2009;31: 793-801.
17. Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res 2001;7:3437-43.
18. Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL, Castro- Santos P, Bayon GF, Ferrero C, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab 2013;98:2811-21.
19. Cheng Y, Geng H, Cheng SH, Liang P, Bai Y, Li J, et al.KRABzinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res 2010;70:6516-26.
20. Li L, Ying J, Li H, Zhang Y, Shu X, Fan Y, et al. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/b-catenin signaling and silenced in common carcinomas. Oncogene 2012;31:3901-12.
21. Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 2006;25: 1070-80.
22. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002;11:2091-102.
23. Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, et al. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 2004;23:4793-806.
24. Li L, Tao Q, Jin H, van Hasselt A, Poon FF, Wang X, et al. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res 2010;16:2949-58.
25. Xu L, Li X, Chu ES, Zhao G, Go MY, Tao Q, et al. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Gut 2011;61:977-85.
26. Shu XS, Li L, Ji M, Cheng Y, Ying J, Fan Y, et al. FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. Carcinogenesis 2013;34:1984-93.
27. Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCRbased analysis. Am J Pathol 1999;155:619-25.
28. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, et al. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/b-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 2008;14:55-61.
29. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
30. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001;12:397-408.
31. Marcoux N, Vuori K. EGF receptor activity is essential for adhesioninduced stress fiber formation and cofilin phosphorylation. Cell Signal 2005;17:1449-55.
32. Toral C, Solano-Agama C, Reyes-Marquez B, Sabanero M, Talamás P, González del Pliego M, et al. Role of extracellular matrix-cell interaction and epidermal growth factor (EGF) on EGF-receptors and actin cytoskeleton arrangement in infantile pituitary cells. Cell Tissue Res 2007; 327:143-53.
33. Suga A, Hikasa H, Taira M. Xenopus ADAMTS1 negatively modulates FGF signaling independent of its metalloprotease activity. Dev Biol 2006;295:26-39.
34. Llamazares M, Obaya AJ,Moncada-Pazos A, Heljasvaara R, Espada J, López-Otín C, et al. The ADAMTS12 metalloproteinase exhibits antitumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci 2007;120(Pt 20):3544-52.
35. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009;15: 1140-4.
36. Collins-Racie LA, Flannery CR, Zeng W, Corcoran C, Annis-Freeman B, Agostino MJ, et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol 2004;23:219-30.
37. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 2003;100:12718-23.
38. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128-37.
39. Nakada M, Miyamori H, Kita D, Takahashi T, Yamashita J, Sato H, et al. Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol 2005;110:239-46.